Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN).

Full DD Report for BMRN

You must become a subscriber to view this report.


Recent News from (NASDAQ: BMRN)

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global...
Source: SeekingAlpha
Date: September, 07 2018 07:32
Gene therapy players under pressure
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks ...
Source: SeekingAlpha
Date: September, 05 2018 10:58
BioMarin Announces 20 Poster Presentations at Society for the Study of Inborn Errors of Metabolism (SSIEM) Symposium 2018
SAN RAFAEL, Calif. , Sept. 5, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present 20 poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Symposium 2018, which will be held on September 4-7 in...
Source: PR Newswire
Date: September, 05 2018 08:30
FDA OK's Bayer's Jivi for hemophilia A
The FDA approves Bayer's ( OTCPK:BAYRY ) Jivi (antihemophilic factor [recombinant] PEGylated-aucl) for the routine prophylactic treatment of hemophilia A in previously treated patients at least 12 years old. More news on: Bayer A.G. ADR, Catalyst Biosciences, Inc., Sangamo Therapeutics, ...
Source: SeekingAlpha
Date: August, 30 2018 07:37
Ultragenyx's Mepsevii OK'd in Europe for MPS VII
As expected, the European Commission approves Ultragenyx's Mepsevii (vestronidase alfa) for the treatment of non-neurological manifestations of mucopolysaccharidosis VII (MPS VII) of Sly syndrome, a rare inherited lysosomal storage disorder. More news on: REGENXBIO, Sangamo Therapeutics,...
Source: SeekingAlpha
Date: August, 27 2018 16:12
Money flow stays positive in biotechs, XBI up 6% since last week
Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped  6%  since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the ...
Source: SeekingAlpha
Date: August, 27 2018 11:39
BioMarin to Participate in Three Investor Conferences in September
SAN RAFAEL, Calif. , Aug. 22, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in three investor conferences this September.  To access the events that are accessible by live webcasts, please visit the investor se...
Source: PR Newswire
Date: August, 22 2018 08:30
FDA and NIH to loosen oversight of gene therapy development
Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study...
Source: SeekingAlpha
Date: August, 16 2018 09:47
Express Scripts quietly building dispensing business for pricey meds
Reuters reports that Express Scripts ( ESRX +0.3% ) is in talks with BioMarin Pharmaceutical ( BMRN -1.2% ), Spark Therapeutics ( ONCE -2.6% ) and bluebird bio ( BLUE -2.1% ) aimed at exclusive dispensing of their pricey hemophilia treatments after regulatory approval, expected in ...
Source: SeekingAlpha
Date: August, 15 2018 11:01
Investors shun healthcare stocks in broad market selloff
Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc...
Source: SeekingAlpha
Date: August, 15 2018 10:14

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0896.0898.0498.4895.531,121,032
2018-08-2499.0098.7699.1697.55752,357
2018-08-23101.2499.09101.3098.89952,361
2018-08-2299.61101.53101.9499.32562,446
2018-08-2199.5899.74100.30599.0551,200,492

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-12128,814246,51352.2544Short
2018-12-1138,38999,70038.5045Short
2018-12-1051,071252,11920.2567Cover
2018-12-0744,127109,88040.1593Short
2018-12-06110,551220,05950.2370Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BMRN.


About BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN)

Logo for BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $15,822,910,136 - 05/14/2018
  • Issue and Outstanding: 176,713,314 - 04/13/2018

 


Recent Filings from (NASDAQ: BMRN)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 26 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 26 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 26 2018

 

 


Daily Technical Chart for (NASDAQ: BMRN)

Daily Technical Chart for (NASDAQ: BMRN)


Stay tuned for daily updates and more on (NASDAQ: BMRN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BMRN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BMRN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BMRN and does not buy, sell, or trade any shares of BMRN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/